Market Overview:
The global hemophilia treatment drugs market is expected to grow at a CAGR of 5.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of hemophilia, rising awareness about available treatments, and technological advancements in the field of hemophilia treatment drugs. Hemophilia is a rare bleeding disorder that affects approximately 1 in 5,000 males worldwide. There are three types of hemophilia: A, B, and C. Hemophilia A is the most common type and accounts for approximately 80% of all cases. The other two types are much less common.
Product Definition:
Hemophilia is a bleeding disorder that affects men and women. Hemophilia is caused by an inherited deficiency in one of the proteins needed to make blood clot. As a result, people with hemophilia may experience uncontrolled bleeding, even from minor injuries. There are three types of hemophilia: A, B, and C. Hemophilia A is the most common type and accounts for about 80% of all cases.
People with hemophilia often require regular injections of factor VIII or IX (hemophilia treatment drugs) to help their blood clot properly.
Recombinant Coagulation Factor Concentrates:
Recombinant coagulation factor concentrates (rFVC), also known as plasma-derived factor V, is a protein that plays an important role in the normal blood clotting process. The deficiency of rFVC leads to Hemophilia treatment drugs (HTR) which are severe bleeding disorders caused by a lack of proper blood clotting. According to data published by the National Library of Medicine, around 30,000 - 40,000 cases are registered every year in U.
Plasma Derived Coagulation Factor Concentrates:
Plasma derived coagulation factor concentrates are used in the treatment of hemophilia. It helps to prevent bleeding by enhancing the blood clotting mechanism. Plasma-derived coagulation factor concentrates (POCF) market is expected to witness lucrative growth over the forecast period owing to increasing prevalence of hemophilia and growing demand for effective treatment options.
Application Insights:
Based on application, the global market is segmented into hospital pharmacies, retail pharmacies and e-commerce. The hospital pharmacy segment dominated the market in 2017 owing to factors such as high patient visits due to bleeding disorders and a higher prevalence of factor deficiency among hemophilia patients. Moreover, this segment is expected to grow at a lucrative rate during the forecast period owing to an increase in healthcare expenditure globally.
The retail pharmacy segment is anticipated to witness significant growth over the forecast period due largely by increasing awareness about treatment options among hemophilia patients coupled with rising availability of treatment drugs through online channels at affordable prices as compared to that prevailing in hospitals. This has resulted in growing preference for self-treatment by individuals suffering from hemophilia without consulting doctors or seeking medical advice which further increases demand for these drugs through direct purchase from pharmaceutical companies or via online e-commerce portals.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable reimbursement policies, and availability of technologically advanced products are some factors responsible for its growth. In addition, increasing prevalence of bleeding disorders is also expected to drive the regional market over the forecast period. According to data published by National Institute of Health (NIH), about 1 million people suffer fromvon Recklinghausen's disease in U.S., which causes internal bleeding and organ damage; it is one type among many other rare diseases associated with hemophilia A & B that need regular treatment with factor concentrates or replacement therapy in developed countries like U.S.
Growth Factors:
- Increasing incidence of hemophilia
- Growing demand for better and more effective hemophilia treatments
- Advances in hemophilia treatment drugs research and development
- Emergence of novel therapies for the treatment of hemophilia
- Expansion of the global hematology market
Scope Of The Report
Report Attributes
Report Details
Report Title
Hemophilia Treatment Drugs Market Research Report
By Type
Recombinant Coagulation Factor Concentrates, Plasma Derived Coagulation Factor Concentrates, Desmopressin, Antifibrinolytic Agents
By Application
Hospital Pharmacies, Retail Pharmacies, E-commerce
By Companies
Pfizer, Biotest, CSL Behring, Kedrion, Octapharma, Takeda, Novo Nordisk, Bayer, Roche, Biogen, Pfizer
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
145
Number of Tables & Figures
102
Customization Available
Yes, the report can be customized as per your need.
Global Hemophilia Treatment Drugs Market Report Segments:
The global Hemophilia Treatment Drugs market is segmented on the basis of:
Types
Recombinant Coagulation Factor Concentrates, Plasma Derived Coagulation Factor Concentrates, Desmopressin, Antifibrinolytic Agents
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacies, Retail Pharmacies, E-commerce
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Biotest
- CSL Behring
- Kedrion
- Octapharma
- Takeda
- Novo Nordisk
- Bayer
- Roche
- Biogen
- Pfizer
Highlights of The Hemophilia Treatment Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Recombinant Coagulation Factor Concentrates
- Plasma Derived Coagulation Factor Concentrates
- Desmopressin
- Antifibrinolytic Agents
- By Application:
- Hospital Pharmacies
- Retail Pharmacies
- E-commerce
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Hemophilia Treatment Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Hemophilia treatment drugs are medications that help to prevent or control bleeding. These medications can be used to treat hemophilia A, B, and C.
Some of the key players operating in the hemophilia treatment drugs market are Pfizer, Biotest, CSL Behring, Kedrion, Octapharma, Takeda, Novo Nordisk, Bayer, Roche, Biogen, Pfizer.
The hemophilia treatment drugs market is expected to grow at a compound annual growth rate of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Hemophilia Treatment Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Hemophilia Treatment Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Hemophilia Treatment Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Hemophilia Treatment Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Hemophilia Treatment Drugs Market Size & Forecast, 2020-2028
4.5.1 Hemophilia Treatment Drugs Market Size and Y-o-Y Growth
4.5.2 Hemophilia Treatment Drugs Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Recombinant Coagulation Factor Concentrates
5.2.2 Plasma Derived Coagulation Factor Concentrates
5.2.3 Desmopressin
5.2.4 Antifibrinolytic Agents
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital Pharmacies
6.2.2 Retail Pharmacies
6.2.3 E-commerce
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Hemophilia Treatment Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Hemophilia Treatment Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Recombinant Coagulation Factor Concentrates
9.6.2 Plasma Derived Coagulation Factor Concentrates
9.6.3 Desmopressin
9.6.4 Antifibrinolytic Agents
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital Pharmacies
9.10.2 Retail Pharmacies
9.10.3 E-commerce
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Recombinant Coagulation Factor Concentrates
10.6.2 Plasma Derived Coagulation Factor Concentrates
10.6.3 Desmopressin
10.6.4 Antifibrinolytic Agents
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital Pharmacies
10.10.2 Retail Pharmacies
10.10.3 E-commerce
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Recombinant Coagulation Factor Concentrates
11.6.2 Plasma Derived Coagulation Factor Concentrates
11.6.3 Desmopressin
11.6.4 Antifibrinolytic Agents
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital Pharmacies
11.10.2 Retail Pharmacies
11.10.3 E-commerce
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Recombinant Coagulation Factor Concentrates
12.6.2 Plasma Derived Coagulation Factor Concentrates
12.6.3 Desmopressin
12.6.4 Antifibrinolytic Agents
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital Pharmacies
12.10.2 Retail Pharmacies
12.10.3 E-commerce
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Recombinant Coagulation Factor Concentrates
13.6.2 Plasma Derived Coagulation Factor Concentrates
13.6.3 Desmopressin
13.6.4 Antifibrinolytic Agents
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital Pharmacies
13.10.2 Retail Pharmacies
13.10.3 E-commerce
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Hemophilia Treatment Drugs Market: Competitive Dashboard
14.2 Global Hemophilia Treatment Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Pfizer
14.3.2 Biotest
14.3.3 CSL Behring
14.3.4 Kedrion
14.3.5 Octapharma
14.3.6 Takeda
14.3.7 Novo Nordisk
14.3.8 Bayer
14.3.9 Roche
14.3.10 Biogen
14.3.11 Pfizer
